Chimerix ^Public

Chimerix is a biotechnology company focused on developing therapeutics for antiviral diseases. Their lead candidate, CMX001, is a potential broad spectrum antiviral agent for the treatment of life-threatening double-stranded DNA viral diseases. They have conducted clinical studies on CMX001 for the prevention/control of cytomegalovirus (CMV) and adenovirus (AdV) infections, as well as for the treatment of various other dsDNA viral infections. Chimerix has also developed a second clinical-stage antiviral compound, CMX157, for the treatment of HIV infection. They are actively pursuing new treatments for hepatitis C virus, flu, malaria, and other global public health needs.